



Higher Order Structure Characterization of Therapeutic Antibodies- Second Volume

Guest Editor:

Dr. Aaron T. Wecksler

Department of Protein Analytical
Chemistry, Genentech, Inc.,
Member of the Roche Group 1
DNA Way, South San Francisco,
CA 94080, USA

Deadline for manuscript
submissions:

closed (31 March 2023)

Message from the Guest Editor

This Special Issue of *Antibodies* focuses on techniques for the structural characterization of biotherapeutic antibodies. The unique structure of therapeutic monoclonal antibodies (mAbs) enables highly specific target recognition, affords the potential for multiple modes of mechanisms of actions (MoAs), and aids in the evasion of foreign recognition by the immune system. The higher order structure (HOS) of mAbs is an inherent critical quality attribute (CQA), and perturbations in the HOS can lead to immunogenicity and/or loss of efficacy. Thus, techniques that enable direct and indirect structural characterization are integral for the development and product quality consistency of mAbs. This Special Issue aims to highlight both traditional and emerging technologies for HOS characterization with an emphasis on studies on the relationship between structure and function, critical quality attribute assessments, immunogenicity, pharmacokinetics, and structural comparability.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Arne Skerra

Chair of Biological Chemistry,
Technical University of Munich,
Emil-Erlenmeyer-Forum 5, 85354
Freising (Weihenstephan),
Germany

Message from the Editor-in-Chief

Antibodies is a relatively new journal with a major focus on quick dissemination of knowledge related to antibodies, especially how to quickly translate basic research results to therapeutic applications. Because it covers all areas related to antibodies unexpected connections between different areas could be made, leading to major discoveries and opening new fields of research and development. This is enhanced by the large readership of the many antibody-related areas of research. A specific priority area is human monoclonal antibodies for therapy of diseases and aging.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, ESCI (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank: CiteScore - Q2 (Drug Discovery)

Contact Us

Antibodies Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibodies
antibodies@mdpi.com
X@Antibodies_MDPI